13F Holdings
中文EN

KPTI Karyopharm Therapeutics Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1503802 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY6.8%
TTM net income YoY-81.9%
TTM EPS YoY-2.7%
Revenue 3-yr CAGR0.1%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-56.2%
Net margin-153.3%
FCF margin—
EBITDA margin-56.1%

Returns

ROE—
ROA-207.9%
ROIC (approx.)—
Asset turnover1.36x

Leverage & solvency

Liabilities / assets396.6%
Debt / equity—
Current ratio0.79x
Interest coverage-1.67x

Cash quality & payout

Operating cash flow / net income0.29x
Accruals ratio-147.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$146.07M$145.24M$146.03M$157.07M$20.00M
R&D expense$125.62M$143.23M$138.75M$148.66M$160.84M
SG&A expense$105.21M$115.44M$131.88M$145.40M$143.85M
Operating income-$90.71M-$119.44M-$129.54M-$142.20M-$98.27M
Interest expense$45.85M$37.42M$23.82M$25.00M$26.05M
Pretax income-$196.00M-$76.36M-$142.78M-$164.92M-$123.82M
Income tax$43,000$57,000$323,000$369,000$268,000
Net income-$196.04M-$76.42M-$143.10M-$165.29M-$124.09M
EBITDA-$90.41M-$119.10M-$129.01M-$141.58M-$97.48M
EPS (basic)-17.93-9.41-18.79-2.02-1.65
EPS (diluted)-17.93-14.00-18.79-2.02-1.65
Weighted avg. shares (diluted)10,9358,4557,61681,87175.22M
Balance sheet
Cash & equivalents$60.54M$62.81M$52.23M$136.88M$197.44M
Short-term investments$3.20M$46.24M$139.21M$142.78M$38.16M
Receivables$26.18M$30.77M$26.96M$47.09M$22.50M
Inventory$4.04M$4.74M$3.04M$4.22M$4.11M
Current assets$103.15M$156.46M$233.92M$350.16M$275.61M
PP&E, net$104,000$400,000$606,000$1.14M$1.64M
Total assets$108.42M$164.42M$240.44M$358.17M$305.31M
Current liabilities$92.06M$92.26M$69.48M$65.91M$73.72M
Long-term debt————$169.29M
Total debt————$169.29M
Total liabilities$401.34M$350.44M$376.64M$374.83M$384.98M
Shareholders' equity-$292.93M-$186.02M-$136.21M-$16.66M-$79.67M
Net debt————-$28.15M
Shares outstanding18.31M8.41M114.92M113.21M75.75M
Cash flow statement
Operating cash flow-$75.37M-$127.49M-$92.72M-$149.55M-$107.12M
Capital expenditure$0$142,000$0$118,000$212,000
Free cash flow-$75.37M-$127.63M-$92.72M-$149.67M-$107.33M
Investing cash flow$43.38M$95.47M$7.94M-$104.26M$141.84M
Financing cash flow$30.05M$41.65M$1.12M$193.74M$73.65M
Depreciation & amortization$296,000$340,000$530,000$621,000$789,000
Stock-based compensation$14.05M$18.43M$21.71M$35.40M$29.78M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.